Physician profile

Gary Joel Rosenberg

Orthopaedic Surgery of the Spine · Newport Beach, CA

NPI 1619275203

$47,789.91

in general payments reported to CMS, 2019-2025

30 companies · $1,310 in 2025

The $1,310 reported for 2025 was less than what a typical Orthopaedic Surgery of The Spine provider received nationally (typical 2025 total: $2,116).

See the full distribution for Orthopaedic Surgery of the Spine

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$4,925.00
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$4,000.00
Food and Beverage$1,107.28

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Innovasis INC $25,413.25 2021-2024
Cerapedics INC. $3,683.23 2021
Medical Device Business Services, INC. $3,567.41 2019-2021
Depuy Synthes Products, INC. $3,179.60 2020
Depuy Synthes Sales INC. $2,876.50 2019-2022
Kyocera Medical Technologies, INC. $2,642.63 2022-2025
Novapproach Spine, LLC $2,500.00 2023 Onelif
Camber Spine Technologies LLC $1,032.14 2021
Orthofix Medical, INC. $802.13 2021-2022
Brainlab, INC. $535.77 2019
Neo Spine USA, INC. $259.79 2025 Neo Pedicle Screw System
Stryker Corporation $255.00 2019-2022
Cpm Medical Consultants, LLC $221.54 2021
Spineology INC. $201.54 2023 Optimesh Expandable Interbody Fusion System
Zimmer Biomet Holdings, INC. $110.07 2019-2020
Show all 30 companies
CompanyGeneral paymentsYearsTop products
Osteocentric Technologies, INC. $71.98 2023 Osteocentric 4.0 X 130mm Locking Bone Screw Fastener St
Medtronic, INC. $54.71 2021
Ethicon US, LLC $49.93 2019
Convatec INC. $42.44 2019
Nuvasive, INC. $41.95 2020
Abbott Laboratories $41.85 2023 Eterna, Proclaim
Medtronic USA, INC. $33.26 2019
Globus Medical, INC. $28.20 2022
Nevro Corp. $28.05 2019
Baxter Healthcare $27.75 2019
Mallinckrodt Enterprises LLC $27.56 2019
Nalu Medical, INC. $20.27 2024 Nalu Neurostimulation System
Integrity Implants INC. $16.71 2021
Lemaitre Vascular, INC. $13.75 2019
Augmedics INC. $10.90 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$4,875.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

$12,012.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Gary Joel Rosenberg

$47,789.91

in general payments reported 2019-2025

Years
2019-2025
Top company
Innovasis INC
Context
The $1,310 reported for 2025 was less than what a typical Orthopaedic Surgery of The Spine provider received nationally (typical 2025 total: $2,116).

https://glasscript.com/doctor/1394824/gary-joel-rosenberg

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.